All

API

FDF

Price

Services

Excipients

Enquiries

Find

Active Pharmaceutical Ingredients
Finished Drug Formulations
Price
Excipients
Services
Marketplace

Market Place

Post Enquiry

Grow Your Pharma Business Digitally

Scorr-Insert

X

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

A collaboration with SCORR Marketing

All Data

Filters

refresh

×

FILTER DATA :

News Type

Company

Product Type

Deal Size

Upfront Payment

refresh

Product Type

Companies

TolerogenixX

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

GERMANY Germany

Post An Enquiry

ASCO 2020

Participation Not Confirmed

Update your events

TolerogenixX Reports Positive Phase Ib Data of its Lead Product to Combat Transplant Rejection

Contact the Supplier

Lead Product(s): MIC-Lx

Therapeutic Area: Immunology

Highest Development Status: Phase I Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable May 11, 2020

Details:

The so-called TOL-1 study met all endpoints and demonstrated the feasibility and safety of MIC-Lx administration in inducing donor-specific tolerance in kidney transplant recipients.